These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 24942388)

  • 1. Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study.
    Chen Q; Sjölander A; Runeson B; D'Onofrio BM; Lichtenstein P; Larsson H
    BMJ; 2014 Jun; 348():g3769. PubMed ID: 24942388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database.
    McCarthy S; Cranswick N; Potts L; Taylor E; Wong IC
    Drug Saf; 2009; 32(11):1089-96. PubMed ID: 19810780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.
    Schulz KP; Fan J; Bédard AC; Clerkin SM; Ivanov I; Tang CY; Halperin JM; Newcorn JH
    Arch Gen Psychiatry; 2012 Sep; 69(9):952-61. PubMed ID: 22945622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.
    Weisler RH; Pandina GJ; Daly EJ; Cooper K; Gassmann-Mayer C;
    CNS Drugs; 2012 May; 26(5):421-34. PubMed ID: 22519922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
    Garnock-Jones KP; Keating GM
    Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): an open-label prospective study of time in treatment, dose, side-effects and comorbidity.
    Fredriksen M; Dahl AA; Martinsen EW; Klungsøyr O; Haavik J; Peleikis DE
    Eur Neuropsychopharmacol; 2014 Dec; 24(12):1873-84. PubMed ID: 25453480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults.
    Santosh PJ; Sattar S; Canagaratnam M
    CNS Drugs; 2011 Sep; 25(9):737-63. PubMed ID: 21870887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability.
    Treuer T; Gau SS; Méndez L; Montgomery W; Monk JA; Altin M; Wu S; Lin CC; Dueñas HJ
    J Child Adolesc Psychopharmacol; 2013 Apr; 23(3):179-93. PubMed ID: 23560600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: a review of controlled and naturalistic studies.
    Fredriksen M; Halmøy A; Faraone SV; Haavik J
    Eur Neuropsychopharmacol; 2013 Jun; 23(6):508-27. PubMed ID: 22917983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.
    Wu EQ; Birnbaum HG; Zhang HF; Ivanova JI; Yang E; Mallet D
    J Manag Care Pharm; 2007 Sep; 13(7):561-9. PubMed ID: 17874862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study.
    Wong IC; Asherson P; Bilbow A; Clifford S; Coghill D; DeSoysa R; Hollis C; McCarthy S; Murray M; Planner C; Potts L; Sayal K; Taylor E
    Health Technol Assess; 2009 Oct; 13(50):iii-iv, ix-xi, 1-120. PubMed ID: 19883527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Injury prevention by medication among children with attention-deficit/hyperactivity disorder: a case-only study.
    Mikolajczyk R; Horn J; Schmedt N; Langner I; Lindemann C; Garbe E
    JAMA Pediatr; 2015 Apr; 169(4):391-5. PubMed ID: 25686215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atomoxetine in the treatment of attention deficit hyperactivity disorder and suicidal ideation.
    Capuano A; Scavone C; Rafaniello C; Arcieri R; Rossi F; Panei P
    Expert Opin Drug Saf; 2014 Sep; 13 Suppl 1():S69-78. PubMed ID: 25171160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain.
    Hong J; Dilla T; Arellano J
    BMC Psychiatry; 2009 Apr; 9():15. PubMed ID: 19366449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
    Roskell NS; Setyawan J; Zimovetz EA; Hodgkins P
    Curr Med Res Opin; 2014 Aug; 30(8):1673-85. PubMed ID: 24627974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of suicide attempts in adolescents and young adults with attention-deficit hyperactivity disorder: a nationwide longitudinal study.
    Huang KL; Wei HT; Hsu JW; Bai YM; Su TP; Li CT; Lin WC; Tsai SJ; Chang WH; Chen TJ; Chen MH
    Br J Psychiatry; 2018 Apr; 212(4):234-238. PubMed ID: 29501070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom.
    Cottrell S; Tilden D; Robinson P; Bae J; Arellano J; Edgell E; Aristides M; Boye KS
    Value Health; 2008; 11(3):376-88. PubMed ID: 18489664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder : clinical approaches and review of current available evidence.
    Prasad S; Steer C
    Paediatr Drugs; 2008; 10(1):39-47. PubMed ID: 18162007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.
    Gibson AP; Bettinger TL; Patel NC; Crismon ML
    Ann Pharmacother; 2006 Jun; 40(6):1134-42. PubMed ID: 16735655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.